In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until disease progression or the participants are unable to tolerate the study drugs. Probable new methods for that analysis and treatment of AML. (A) The identification https://eduardoyjufs.dailyhitblog.com/37488598/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described